

Press release from Biora AB (publ), April 29, 2003

N o 8 / 0 3

FOR IMMEDIATE

R E L E A S E

Biora Annual General Meeting held on April 29th in Malmö, Sweden

At the Annual General Meeting "AGM" in Malmö, Sweden today, six of the ordinary members of the Board of Directors were reelected. Jan Kvarnström, member of Biora Board since January 2002 and Lennart Jacobsson, deputy Board member declined reelection due to changed responsibilities. A new Deputy Director, Håkan Bohlin was elected. Shareholders at the Annual General meeting adopted the Board of Directors' proposal to amend the Articles of Association regarding notices of extraordinary meetings. In the future, notices will not be mailed directly to shareholders but will be made through a public announcement.

Shareholders fixed the total annual fee for Directors which will remain unchanged at SEK 800,000, to be allocated as determined by the Board of Directors. Additionally, Shareholders at the Annual General Meeting approved the Board of Directors' proposal that the accumulated loss on the Parent Company's balance sheet will be charged to the share premium reserve.

The Swedish Shareholders Organization, who made a proposal regarding committees, was not present at the AGM, therefore no decision was taken regarding this matter.

Biora develops manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain[®] Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden.

This press release may contain certain forward-looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission.

For further information, please contact:

- Svante Lundell, CFO and Investor Relations, Biora + 46-70 532 30 65
- Donna Janson, President and CEO of Biora, tel: $+\ 4\ 6\ -\ 4\ 0\ -\ 3\ 2\ 1\ 2\ 8$
- http://www.biora.com